StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value
$3.05+0.09 (+3.04%)

Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –

Protalix BioTherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Protalix BioTherapeutics's price to sales ratio was 3.2× on Nov 11, 2026, against 2.5× a year earlier. Over the last 5 years it ranged from 0.7× to 4.4×, with a median of 2.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.2×+0.7
2025Dec 31, 20252.5×−0.7
2024Dec 31, 20243.2×+1.3
2023Dec 29, 20231.9×+0.6
2022Dec 30, 20221.4×+0.7
2021Dec 31, 20210.7×−0.2
2020Dec 31, 20200.9×+0.1
2019Dec 31, 20190.8×−2.0
2018Apr 30, 20182.8×−2.1
2017Dec 29, 20174.9×−1.4
2016Dec 30, 20166.3×−8.4
2015Dec 31, 201514.7×+2.4
2014Dec 31, 201412.3×−26.3
2013Dec 31, 201338.6×+25.7
2012Dec 31, 201213.0×−41.4
2011Jul 29, 201154.3×–

More Protalix BioTherapeutics figures

See a number that looks wrong?